| Drugs by Condition |  |
Hypogonadism, Male Medications
Drugs (by generic name) associated with Hypogonadism, Male
The following drugs and medications are in some way related to, or used in the treatment of Hypogonadism, Male. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
||
|---|---|---|---|---|
testosterone systemic (Pro, More...) class: androgens and anabolic steroids | 34 review(s) |  | 7.8 | |
| chorionic gonadotropin (hcg) systemic (More...)class: gonadotropins | 0 review(s) | | 2.5 | |
| methyltestosterone systemic (Pro, More...)class: androgens and anabolic steroids | 0 review(s) | Not rated - Be the first | ||
| follicle stimulating hormone systemic (Pro, More...)class: gonadotropins | 0 review(s) | Not rated - Be the first | ||
| fluoxymesterone systemic (Pro, More...)class: androgens and anabolic steroids, hormones/antineoplastics | 0 review(s) | Not rated - Be the first | ||
See also...
Hypogonadism, Male Medications in the Pipeline
Nebido (testosterone undecanoate)
- September 3, 2009 - Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
- March 12, 2009 - FDA Accepts Complete Response Submission to New Drug Application for Nebido
- September 26, 2008 - Indevus and FDA Agree on Path Forward for Nebido
- June 30, 2008 - Indevus Receives Approvable Letter from FDA for Nebido
- June 4, 2008 - Indevus Pharmaceuticals Provides Update on Nebido NDA Status
- November 1, 2007 - FDA Accepts New Drug Application for Nebido Submitted by Indevus
- August 28, 2007 - Indevus Announces Submission of New Drug Application for Nebido
Fortesta (testosterone)
Latest Hypogonadism, Male Blog Post
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
Long-term Data Presented at AUA Annual Meeting
CHICAGO, April 28 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (NASDAQ: ENDP) today released new long-term clinical trial data in men with hypogonadism who were treated for 21 months with testosterone...
View all Hypogonadism, Male blog posts.
